102 related articles for article (PubMed ID: 15618365)
21. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging.
Reimer P; Müller M; Marx C; Wiedermann D; Muller R; Rummeny EJ; Ebert W; Shamsi K; Peters PE
Radiology; 1998 Dec; 209(3):831-6. PubMed ID: 9844683
[TBL] [Abstract][Full Text] [Related]
22. Iron particle labeling of haematopoietic progenitor cells: an in vitro study.
de Laquintane BD; Dousset V; Solanilla A; Petry KG; Ripoche J
Biosci Rep; 2002; 22(5-6):549-54. PubMed ID: 12635852
[TBL] [Abstract][Full Text] [Related]
23. Iron oxides as MR imaging contrast agents.
Fahlvik AK; Klaveness J; Stark DD
J Magn Reson Imaging; 1993; 3(1):187-94. PubMed ID: 8428086
[No Abstract] [Full Text] [Related]
24. Liver MR imaging with iron oxides: toward consensus and clinical practice.
Weissleder R
Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
[No Abstract] [Full Text] [Related]
25. Inflammatory pseudotumor of the liver: ferumoxide-enhanced MR imaging as a tiebreaker.
Kato H; Kanematsu M; Kondo H; Osada S; Goshima S; Yamada T; Yamada Y; Yokoyama R; Hoshi H; Moriyama N
J Magn Reson Imaging; 2004 Sep; 20(3):501-5. PubMed ID: 15332259
[TBL] [Abstract][Full Text] [Related]
26. Re: Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer.
Kroon BK; Horenblas S
J Urol; 2006 Mar; 175(3 Pt 1):1174. PubMed ID: 16469648
[No Abstract] [Full Text] [Related]
27. Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients.
Barentsz JO; Fütterer JJ; Takahashi S
Eur J Radiol; 2007 Sep; 63(3):369-72. PubMed ID: 17689215
[TBL] [Abstract][Full Text] [Related]
28. Abdominal iron deposition: metabolism, MR findings, and clinical importance.
Siegelman ES; Mitchell DG; Semelka RC
Radiology; 1996 Apr; 199(1):13-22. PubMed ID: 8633135
[No Abstract] [Full Text] [Related]
29. Stem cell implantation in ischemic mouse heart: a high-resolution magnetic resonance imaging investigation.
Küstermann E; Roell W; Breitbach M; Wecker S; Wiedermann D; Buehrle C; Welz A; Hescheler J; Fleischmann BK; Hoehn M
NMR Biomed; 2005 Oct; 18(6):362-70. PubMed ID: 15948224
[TBL] [Abstract][Full Text] [Related]
30. Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US.
Hagspiel KD; Neidl KF; Eichenberger AC; Weder W; Marincek B
Radiology; 1995 Aug; 196(2):471-8. PubMed ID: 7617863
[TBL] [Abstract][Full Text] [Related]
31. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging.
Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM
Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550
[TBL] [Abstract][Full Text] [Related]
32. Target-specific superparamagnetic MR contrast agents.
Weissleder R
Magn Reson Med; 1991 Dec; 22(2):209-12; discussion 213-5. PubMed ID: 1812348
[No Abstract] [Full Text] [Related]
33. Important considerations in the design of iron oxide nanoparticles as contrast agents for TI-weighted MRI and MRA.
Kellar KE; Fujii DK; Gunther WH; Briley-Saebø K; Bjornerod A; Spiller M; Koenig SH
Acad Radiol; 2002 May; 9 Suppl 1():S34-7. PubMed ID: 12019889
[No Abstract] [Full Text] [Related]
34. In vivo MR imaging of tissue-engineered human mesenchymal stem cells transplanted to mouse: a preliminary study.
Ko IK; Song HT; Cho EJ; Lee ES; Huh YM; Suh JS
Ann Biomed Eng; 2007 Jan; 35(1):101-8. PubMed ID: 17111211
[TBL] [Abstract][Full Text] [Related]
35. Magnetic resonance lymphography. Enhancement patterns using superparamagnetic nanoparticles.
Clément O; Guimaraes R; de Kerviler E; Frija G
Invest Radiol; 1994 Jun; 29 Suppl 2():S226-8. PubMed ID: 7928239
[No Abstract] [Full Text] [Related]
36. Comparison between gadopentetate and feruglose (Clariscan)-enhanced MR-mammography: preliminary clinical experience.
Daldrup-Link HE; Kaiser A; Link TM; Settles M; Helbich T; Werner M; Roberts TP; Rummeny EJ
Acad Radiol; 2002 Aug; 9 Suppl 2():S343-7. PubMed ID: 12188270
[No Abstract] [Full Text] [Related]
37. [Superparamagnetic iron particles. The clinical results in the MR diagnosis of liver metastases].
Ham B; Reichel M; Vogl T; Taupitz M; Wolf KJ
Rofo; 1994 Jan; 160(1):52-8. PubMed ID: 8305693
[TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance evaluation of human mesenchymal stem cells in corpus cavernosa of rats and rabbits.
Song YS; Ku JH; Song ES; Kim JH; Jeon JS; Lee KH; Kim SJ; Cheong HJ; Lim IS; Choi D; Won JH
Asian J Androl; 2007 May; 9(3):361-7. PubMed ID: 17486277
[TBL] [Abstract][Full Text] [Related]
39. [MR contrast agent: resovist (SH U 555A)].
Nakajima H; Ichikawa T
Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
[No Abstract] [Full Text] [Related]
40. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles.
Cunningham CH; Arai T; Yang PC; McConnell MV; Pauly JM; Conolly SM
Magn Reson Med; 2005 May; 53(5):999-1005. PubMed ID: 15844142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
